Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Norditek in conjunction with its listing on Nasdaq First North
Mandate

Vinge advises Norditek in conjunction with its listing on Nasdaq First North

November 10, 2021 Capital Markets and Public M&A

Vinge has advised Norditek Group AB in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 10 November 2021. In connection with the listing, an invitation to subscribe for shares for a subscription price of SEK 11 was implemented, which was significantly oversubscribed by approximately 4.5 times.

Norditek Group is an environment technology company which focuses on mobile and flexible recycling stations in the fields of Waste, Sand & Rock and Biomass. The company both develops and sells stations by a tried and tested offering which facilitates cost reductions for its customers at the same time as the customers contribute to a more circular society.

Vinge’s team primarily consisted of Anders Strid, Jenny Sandlund (project manager), Beatrice Randow and Anna Högsten.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025